 Loughborough, England, March 11, 2021 GLOBE NEWSWIRE -- Nemaura Medical, Inc. NASDAQ: NMRD Nemaura or the Company, a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announces its submission to G-BA Gemeinsamer Bundesausschuss for approval of sugarBEAT, the Companys non-invasive, daily wear, continuous glucose monitoring device. 